Literature DB >> 12213843

Guidelines for acromegaly management.

S Melmed1, F F Casanueva, F Cavagnini, P Chanson, L Frohman, A Grossman, K Ho, D Kleinberg, S Lamberts, E Laws, G Lombardi, M L Vance, K Von Werder, J Wass, A Giustina.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12213843     DOI： 10.1210/jc.2002-011841

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  83 in total

1.  Acromegaly: are new tests needed?

Authors:  Anna Spada
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

2.  Dose optimization of somatostatin analogues for acromegaly patients.

Authors:  A Colao; G Lombardi
Journal:  J Endocrinol Invest       Date:  2010-02       Impact factor: 4.256

3.  Assessment of sleep apnea syndrome in treated acromegalic patients and correlation of its severity with clinical and laboratory parameters.

Authors:  L Vannucci; P Luciani; E Gagliardi; S Paiano; R Duranti; G Forti; A Peri
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

Review 4.  GH receptor antagonist: mechanism of action and clinical utility.

Authors:  Sowmya K Surya; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

5.  The learning curve in endoscopic pituitary surgery and our experience.

Authors:  Kenan Koc; Koc Kenan; Ihsan Anik; Anik Ihsan; Dilek Ozdamar; Ozdamar Dilek; Burak Cabuk; Cabuk Burak; Gurkan Keskin; Keskin Gurkan; Savas Ceylan; Ceylan Savas
Journal:  Neurosurg Rev       Date:  2006-08-26       Impact factor: 3.042

6.  Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study.

Authors:  Chris G Yedinak; Maria Fleseriu
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

Review 7.  Acromegaly.

Authors:  Massimo Scacchi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

8.  Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?

Authors:  R Cozzi; R Attanasio; S Grottoli; G Pagani; P Loli; V Gasco; A M Pedroncelli; M Montini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 9.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

10.  Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.

Authors:  A Giustina; T Mancini; P F Boscani; E de Menis; E degli Uberti; E Ghigo; E Martino; F Minuto; A Colao
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.